Bolt Biotherapeutics

About Bolt Biotherapeutics

Bolt Biotherapeutics operates in the biotechnology sector, focusing on the development of advanced immuno-oncology therapies. The company targets patients who do not respond to traditional checkpoint inhibitors, a significant portion of the cancer patient population. Bolt Biotherapeutics' proprietary platform reinvigorates the immune system by leveraging the capabilities of dendritic and other myeloid cells to generate effective anti-tumor immunity. This approach aims to create systemic immunological memory, offering durable clinical benefits. The company primarily serves the healthcare market, specifically targeting oncologists and cancer treatment centers. Bolt Biotherapeutics generates revenue through the development and commercialization of its unique class of immuno-oncology therapies, known as ISACs (Immune-Stimulating Antibody Conjugates). These therapies are designed to provide long-term benefits to cancer patients by enhancing their immune response to tumors.